Merck, slower than its peers, edges into COVID-19 fight

Up until this week Merck, however, has been conspicuously absent from this call; but, in its first-quarter report today, the pharma announced that it is, slowly, looking to join the battle.

The Big Pharma, which reported its financials alongside Pfizer and Novartis Tuesday morning, said it has “embarked upon a broad-based development program for SARS-CoV-2,” the virus causing COVID-19.